Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to assess how effective and tolerable the country specific clinical practice guidelines of SLTs are for UK, France and Sweden are.

The main rationale behind this study is that well controlled comparisons of the various laxatives for the treatment of OIC are lacking. There is lack of evidence suggesting which laxative or combination of laxatives is optimal for managing OIC.


Clinical Trial Description

The study comprises of nine study visits and the total duration of the study is up to 42-52 days Potential subjects, aged 18 years and over, with OIC will be screened for entry into the study at Visit 1 Eligible subjects will attend a 7-day Screening Period (Visit 1). This will be followed by a 28-day Treatment Period (visits 2 to 8:), made up of four clinic visits scheduled 7 days apart (visits 5(day 7), 6(day 14), 7(day 21), 8(day 28): days 7 to 28) and two telephone visits (visits 3 and 4) which will take place during the first week of the Treatment Period. There will be a 7-day Follow-up Period with a follow-up phone call to conclude the study (Visit 9).

Study assessment/ evaluation include vital sign measurements, ECG, safety labs, pregnancy test and physical examination assessments, AEs, Investigator and subject questionnaires and subjects daily diaries.

Subjects will continue to take their prescribed pre-study opioid medication throughout the study. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01957046
Study type Interventional
Source Mundipharma Research GmbH & Co KG
Contact
Status Completed
Phase Phase 4
Start date October 2013
Completion date February 2015

See also
  Status Clinical Trial Phase
Terminated NCT02813369 - Naloxegol Health Outcome Post Authorisation Safety Study
Completed NCT01401985 - A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) Phase 2
Completed NCT00984334 - Naloxone SR Capsules in Patients With Opioid Induced Constipation Phase 2
Completed NCT01207427 - Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain Phase 2
Completed NCT01459926 - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation Phase 2
Terminated NCT01117051 - Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation Phase 3
Completed NCT03060512 - To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Phase 4
Completed NCT01109511 - A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy Phase 4
Active, not recruiting NCT02813356 - Naloxegol US PMR CV Safety.
Completed NCT01812733 - Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives N/A
Completed NCT01623609 - Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol Phase 1
Completed NCT02813148 - Naloxegol Drug Utilization Post Authorisation Safety Study
Completed NCT01443403 - A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy Phase 2
Completed NCT03638440 - Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.